AbbVie (NYSE:ABBV) Stock Price Down 1.1% – Time to Sell?

AbbVie Inc. (NYSE:ABBV)’s share price fell 1.1% during mid-day trading on Friday . The stock traded as low as $213.88 and last traded at $214.38. 7,890,815 shares traded hands during trading, an increase of 5% from the average session volume of 7,532,547 shares. The stock had previously closed at $216.75.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Topline Phase 3 EPCORE DLBCL‑1 results for epcoritamab announced; AbbVie and partner Genmab will engage global regulators on next steps — a clear near‑term commercialization pathway if regulators agree, which supports revenue upside for ABBV’s oncology franchise. PR Newswire: EPCORE topline
• Positive Sentiment: Analyst model upgrades from Zacks: multiple raises to AbbVie’s quarterly and full‑year EPS estimates (FY2026/2027), which can lift sentiment and support higher analyst targets. (Market estimates revisions typically help investor confidence.)
• Positive Sentiment: Pipeline expansion: AbbVie launched first‑in‑human trial for ABBV‑711 (advanced squamous tumors) and reported completion/advancement of other early‑stage programs (including obesity candidate GUB014295 and ABBV‑CLS‑616), diversifying long‑term growth drivers beyond immunology. TipRanks: ABBV‑711 trial
• Neutral Sentiment: Unusually large call‑option activity: a ~2,600% spike in call volume indicates large investors are betting on upside around upcoming catalysts (earnings, regulatory decisions). This is a market signal rather than a fundamental result — it can amplify moves but is not a direct business update. MarketBeat: options spike
• Negative Sentiment: Counterpoint risk: Seeking Alpha reported shares of Genmab fell on trial data for Epkinly (an AbbVie‑partnered B‑cell lymphoma program), which may have created cross‑party market jitters and pressured biotech sector sentiment — any negative readthrough to AbbVie’s partnered assets can weigh on ABBV stock short‑term. Seeking Alpha: Genmab/Epkinly
• Negative Sentiment: Near‑term market weakness: coverage note (Zacks) flagged a recent intraday dip in ABBV while the broader market gained, highlighting investor profit‑taking or rotation despite positive fundamentals. Zacks: stock dip

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ABBV shares. Scotiabank began coverage on shares of AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective for the company. JPMorgan Chase & Co. boosted their price target on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Bank of America upped their price objective on shares of AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. BMO Capital Markets reiterated an “outperform” rating and set a $258.00 target price on shares of AbbVie in a report on Thursday. Finally, Raymond James Financial set a $256.00 price target on AbbVie in a report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $247.84.

AbbVie Stock Down 1.1%

The stock has a market capitalization of $378.89 billion, a price-to-earnings ratio of 162.41, a P/E/G ratio of 0.91 and a beta of 0.36. The company’s fifty day simple moving average is $226.89 and its 200 day simple moving average is $216.08.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s payout ratio is currently 496.97%.

Institutional Trading of AbbVie

Several institutional investors and hedge funds have recently modified their holdings of the stock. Marshall & Sullivan Inc. WA bought a new stake in shares of AbbVie in the 2nd quarter worth $25,000. Evolution Wealth Management Inc. purchased a new position in AbbVie in the 2nd quarter valued at approximately $26,000. Chelsea Counsel Co. bought a new stake in shares of AbbVie during the 3rd quarter valued at $26,000. Spurstone Advisory Services LLC bought a new stake in shares of AbbVie during the second quarter valued at about $28,000. Finally, Westend Capital Management LLC purchased a new position in AbbVie during the fourth quarter valued at approximately $29,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.